Compare Sana Biotechnology Inc (SANA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TKO Group Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while TKO Group Holdings Inc trades at $181.83 (market cap $13.70B). The key difference: TKO Group Holdings Inc is far larger — about 15.7× Sana Biotechnology Inc's market cap, and TKO Group Holdings Inc pays a 1.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TKO | |
|---|---|---|
Market Cap | $873.84M | $13.70B |
Sector | Health | Technology |
52-Week High | $5.92 | $224.96 |
52-Week Low | $2.68 | $155.61 |
Enterprise Value | $848.03M | $17.88B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
TKO trades at $182.79, down 1.26% today, with a bearish technical signal despite strong analyst support. The company shows solid revenue growth with 2026 projections at $5.1B and improved net profit margin of 4.47%. Recent developments include successful international events and an $800 million share repurchase, while earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing.
Wall Street remains bullish with 89% buy ratings and a $228.40 consensus price target, representing 25% upside potential. Key risks include execution on earnings expectations and high valuation multiples. The stock presents a growth opportunity driven by live event demand and media partnerships, though investors should monitor quarterly performance against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
